High LDL/ApoB: Lifestyle, Supplements, or Medication?

Edition #022 helped you find your cardiovascular risk. Edition #023 tackled the major lifestyle drivers. Now your LDL-C or ApoB is still high. What next?

The first mistake is treating the lab number as the whole decision. The second is assuming medication is automatically next.

If you used the PREVENT-ASCVD calculator from Edition #022, pull that 10-year percentage back out. PREVENT combines several risk factors instead of treating LDL-C as a diagnosis by itself, and it was recently validated in more than 680,000 U.S. adults across 30 health systems. [1]

The percentage matters because the same treatment effect can mean very different things. A 25% relative reduction takes a 10% risk to 7.5%, but a 2% risk to 1.5%.

Then add what a calculator cannot fully capture: ApoB, Lp(a), family history and actual plaque when known.

Before deciding how aggressively to lower LDL/ApoB, first confirm the result and what may be driving it.

If the result is surprising or does not fit your usual pattern, repeat it. Also look for an obvious reason it is high, such as a major diet or weight change, low thyroid function, a medication effect or a strong family pattern.

Then ask: how much of a gap are you actually trying to close? A modest gap leaves more room to experiment than very high LDL/ApoB or substantial plaque.

Edition #023 covered the broad cardiovascular lifestyle foundation. Here the goal is narrower: specifically lowering LDL/ApoB.

The main food levers are replacing saturated fat with unsaturated fat, increasing soluble or viscous fiber, and combining foods that lower cholesterol through different mechanisms.

A Portfolio-style diet combines several of those tools, especially viscous fiber, nuts, soy protein and plant sterols. In a six-month randomized trial of 351 people with high cholesterol, the real-world version lowered LDL-C about 13%, or roughly 24 to 26 mg/dL from an average starting LDL of 171 mg/dL. [2]

These effects are not simply additive, but they can stack. Several modest LDL-lowering changes can produce a larger effect together.

A real-world 10% to 15% reduction will not solve every case. But if your gap is modest, it can materially change the medication decision.

Keep three questions separate:

Does it lower my LDL/ApoB?

Does it reduce actual cardiovascular events?

Is it safe enough to use long term?

The first question can often be answered with your own labs.

Psyllium is one of the simplest places to start. Across 28 randomized trials, about 10 grams per day lowered LDL-C by roughly 13 mg/dL on average and also lowered ApoB. [3]

Across 18 randomized placebo-controlled trials, berberine lowered LDL-C by about 18 mg/dL on average and also lowered ApoB in the smaller number of trials that measured it. Most studies were short, so long-term evidence is much thinner than for established drugs. [4]

Red yeast rice has actual cardiovascular-outcome evidence. A standardized Chinese extract reduced major coronary events from 10.4% to 5.7% over about 4.5 years in nearly 5,000 people who had already had a heart attack. [5]

But its active monacolin K is chemically identical to lovastatin. In U.S. retail products, monacolin K content has varied more than 60-fold between brands. [6] So red yeast rice can work, but it is not necessarily a predictable or side-effect-free alternative to a statin.

Other supplements, such as aged garlic extract, bergamot, artichoke leaf extract, probiotics or curcumin, may also be worth testing when the safety profile and product quality are reasonable. Limited commercial incentive for large trials does not mean there is no potential benefit, and anecdotes can help identify candidates worth investigating.

For an objective marker such as ApoB, an N-of-1 experiment can answer an important question: does this intervention meaningfully work for me?

Change one thing, keep the rest reasonably stable, use it consistently for about 8 to 12 weeks, then repeat LDL-C and ApoB. A large, repeatable improvement is useful information. It still does not prove 20-year safety or show that the intervention prevents heart attacks.

Now bring everything together:

What is your ApoB/LDL after the intervention?

What is your PREVENT-ASCVD risk?

Do you have known plaque?

How much additional lowering do you realistically need?

This is where the medication decision should begin.

A strict 2026 meta-analysis of 85,829 people with no previous cardiovascular, vascular or cerebrovascular disease found that lipid-lowering medications reduced heart attacks, strokes and major cardiovascular events, but all-cause mortality was 3.9% in both treatment and control groups during trial follow-up. [7]

A broader 2022 primary-prevention review found a small all-cause mortality reduction of about 0.35 percentage points, along with fewer heart attacks and cardiovascular events. [8]

The fair conclusion: lipid lowering prevents cardiovascular events. Whether that benefit justifies lifelong medication depends heavily on starting risk.

Statins have the deepest cardiovascular-outcome record, but they are not side-effect free.

In large blinded trials, muscle pain or weakness occurred in 27.1% of people taking a statin and 26.6% taking placebo. The excess actually caused by statins was small and concentrated mainly in the first year. [9]

The diabetes effect is clearer. Low- or moderate-intensity statins increased new diabetes diagnoses by about 10% relatively, while high-intensity statins increased them by about 36%, mostly in people already near the diabetes threshold. [10]

Maximum-dose statin is not the only path. In RACING, moderate-dose rosuvastatin plus ezetimibe matched high-dose rosuvastatin for major outcomes and caused fewer intolerance-related dose reductions or discontinuations, 4.8% versus 8.2%. It was open-label, conducted in South Korea and funded by Hanmi Pharmaceutical. [11]

Other drugs have different tradeoffs. Bempedoic acid reduced major cardiovascular events in statin-intolerant, high-risk patients but increased gout and gallstones and did not significantly reduce death overall. [12]

Evolocumab, a PCSK9 inhibitor, reduced 5-year major cardiovascular events from 8.0% to 6.2% in 12,257 high-risk people with atherosclerosis or high-risk diabetes but no previous heart attack or stroke. A prespecified 2026 analysis also found 5-year all-cause mortality of 7.9% versus 9.7%. This was not a low-risk primary-prevention population, and the trial was funded by Amgen. [13] [14]

Inclisiran lowers LDL substantially, but its first dedicated cardiovascular-outcome trial is still awaiting results, expected in early 2027. [15]

The question is whether the likely absolute benefit is large enough to justify the side effects, uncertainty, cost and treatment burden.

If a new symptom or abnormal lab appears after starting a drug, first ask whether the drug caused it before automatically adding another prescription. Prescribing cascades are a documented medical problem, although current evidence does not show that cholesterol drugs routinely start long chains of additional medications. [16]

If your absolute risk is low, you have no known significant plaque and the LDL/ApoB gap is modest, spending 8 to 12 weeks on targeted diet and a carefully chosen supplement experiment can make sense.

That changes if you already have cardiovascular disease, substantial plaque, severe or familial hypercholesterolemia, or otherwise very high cardiovascular risk. Lifestyle and supplements still matter. They just may need to happen alongside effective medication rather than before it.

ApoB-containing particles matter, but the goal is not to drive LDL as low as possible at any cost.

Use the least burdensome approach that produces enough reduction for your actual level of risk. Measure the result. Then decide whether the next step buys enough additional benefit to be worth it.

1.        Know your PREVENT-ASCVD risk and your ApoB/LDL.

2.        If it is safe to wait, spend about 8 to 12 weeks specifically targeting LDL/ApoB with diet and one evidence-backed supplement at a time. Psyllium is the simplest place to start.

3.        Retest.

4.        If ApoB/LDL is still meaningfully high, weigh medication based on the remaining gap, your plaque burden and the absolute benefit you are likely to gain, not the lab number alone.

5.        If you already have cardiovascular disease, major plaque or severe inherited cholesterol elevation, do not delay effective treatment just to exhaust every non-drug option.

Next week in Part 4 (Edition #025): your ApoB is low. Are you actually safe?

This article is for education, not individual medical advice. Do not start, stop or change a prescription medication based on this article. Discuss treatment decisions, supplements and medication changes with your clinician, especially if you have known cardiovascular disease or other medical conditions.

Subscribe free — one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.

1. Khan SS, et al. External Validation of the PREVENT Equations in a National Sample of US Adults. 2026. https://pubmed.ncbi.nlm.nih.gov/42554063/

2. Jenkins DJA, et al. Effect of a Dietary Portfolio of Cholesterol-Lowering Foods on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial. JAMA. 2011. https://pubmed.ncbi.nlm.nih.gov/21862744/

3. Jovanovski E, et al. Effect of Psyllium Fiber on LDL Cholesterol, Non-HDL Cholesterol and Apolipoprotein B. American Journal of Clinical Nutrition. 2018. https://pubmed.ncbi.nlm.nih.gov/30239559/

4. Blais JE, et al. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults. Drugs. 2023. https://pubmed.ncbi.nlm.nih.gov/36941490/

5. Lu Z, et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events After Myocardial Infarction. American Journal of Cardiology. 2008. https://pubmed.ncbi.nlm.nih.gov/18549841/

6. Cohen PA, et al. Variability in Strength of Red Yeast Rice Supplements Purchased From Mainstream Retailers. European Journal of Preventive Cardiology. 2017. https://pubmed.ncbi.nlm.nih.gov/28641460/

7. Morsell B, et al. The Role of Lipid-Lowering Medications in the Primary Prevention of Cardiovascular Disease and Mortality: A Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders. 2026. https://pubmed.ncbi.nlm.nih.gov/41864911/

8. Chou R, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the USPSTF. JAMA. 2022. https://pubmed.ncbi.nlm.nih.gov/35997724/

9. Cholesterol Treatment Trialists' Collaboration. Effect of Statin Therapy on Muscle Symptoms: An Individual Participant Data Meta-Analysis. Lancet. 2022. https://pubmed.ncbi.nlm.nih.gov/36049498/

10. Cholesterol Treatment Trialists' Collaboration. Effects of Statin Therapy on New-Onset Diabetes and Worsening Glycaemia. Lancet Diabetes & Endocrinology. 2024. https://pubmed.ncbi.nlm.nih.gov/38554713/

11. Kim BK, et al. RACING: Moderate-Intensity Statin With Ezetimibe Versus High-Intensity Statin Monotherapy. Lancet. 2022. https://pubmed.ncbi.nlm.nih.gov/35863366/

12. Nissen SE, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/36876740/

13. Bohula EA, et al. Evolocumab in Patients Without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41211925/

14. Giugliano RP, et al. Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. Circulation. 2026. https://pubmed.ncbi.nlm.nih.gov/42670293/

15. Mafham MM, et al. HPS-4/TIMI 65/ORION-4: Trial Design, Recruitment and Baseline Characteristics. American Heart Journal. 2026. https://pubmed.ncbi.nlm.nih.gov/42567431/

16. Carollo M, et al. Prescribing Cascades: An Umbrella Review and Updated Systematic Review. Drugs & Aging. 2026. https://pubmed.ncbi.nlm.nih.gov/41949780/

Evidence disclosure: Several cited studies have relevant commercial funding or author relationships. The Portfolio Diet trial received supplementary food-industry funding; the Xuezhikang trial was partly sponsored by its commercial manufacturer; RACING, CLEAR Outcomes, VESALIUS-CV and ORION-4 received funding from manufacturers of the therapies studied. The CTT statin meta-analyses were independently funded, although some underlying trials were industry-sponsored. Funding does not invalidate the findings, but it is considered when weighing the evidence.